Model‐informed approach to support pediatric dosing for the pan‐PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors

Copanlisib is an intravenously administered phosphatidylinositol 3‐kinase (PI3K) inhibitor which was investigated in pediatric patients with relapsed/refractory solid tumors. A model‐informed approach was undertaken to support and confirm an empirically selected starting dose of 28 mg/m(2) for pedia...

Descripción completa

Detalles Bibliográficos
Autores principales: Morcos, Peter N., Schlender, Jan, Burghaus, Rolf, Moss, Jonathan, Lloyd, Adam, Childs, Barrett H., Macy, Margaret E., Reid, Joel M., Chung, John, Garmann, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339701/
https://www.ncbi.nlm.nih.gov/pubmed/37042099
http://dx.doi.org/10.1111/cts.13523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339701/
https://www.ncbi.nlm.nih.gov/pubmed/37042099
http://dx.doi.org/10.1111/cts.13523

Ejemplares similares